Healthcare Policy, Market Access

PCTs Beware — NICE Compliance Regime Plans Are Here to Stay

PCTs Beware — NICE Compliance Regime Plans Are Here to StayIf Primary Care Trust (PCT) managers in the United Kingdom were a bit worried about government plans for the introduction of a NICE Compliance Regime last month, they should certainly be panicking now. Last week Health Secretary Andrew Lansley told MPs that the plans – first mentioned by Prime Minister David Cameron in December – are not going away.

Last month I examined what the introduction of a NICE Compliance regime will mean to cash-strapped, but the new statements call for the issue to be revisited.

What is New?
In response to a question from Labour MP John Healey, the Health Secretary said last week that existing legislation was clear, but had not always been followed through. “What we will do, and the NHS chief executive is setting out to do, is to show how that will happen in the future,” Lansley announced.

The response clearly refers to the fact that NICE guidance is already meant to be mandatory. Under existing regulations, PCTs have 3 months to start funding NICE-endorsed drugs from the date NICE issues a positive guidance. I previously mentioned that PCTs often fail to adhere to this legal requirement and “blacklist” NICE-endorsed drugs – thus, banning doctors from prescribing them. The practice – known rather infamously as “the postcode lottery” in access to treatment – has been rampant under Labour.

But what can the Coalition government do to end the practice if regulations are already clear but are not being followed through?

A true end to the healthcare postcode lottery?
It will be many months before the details of what the Health Secretary and the NHS Chief Executive are planning become publicly available. A change in regulations may or may not come as a result of these plans. What we would definitely expect to see, however, is a change in the way regulations are enforced.

Enforcement that would end the postcode lottery sounds like an admirable goal. Achieving this goal would provide a government embattled over its healthcare reform plans with the opportunity to take credit for at least one thing – close to the hearts of patients and physicians – that has been done right. Not to mention getting one up on Labour before the next elections.

Details on enforcement action may remain murky for months to come, but there is little doubt in my mind that once they emerge, the full strength of Britain’s coalition government will be thrown into ensuring they are speedily approved and imposed onto PCTs.

“We ended the postcode lottery” would be a great selling point in the next general election after all.

About Milena Izmirlieva

Milena Izmirlieva is a senior manager in the Healthcare practice at IHS. Her areas of expertise include market access, pricing and reimbursement, generics and biosimilars, corporate strategies, and pharma promotion and advertising.

Discussion

No comments yet.

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Connecting to %s

Dynamic Pharma Pricing 2012 Multi Client Study extract download
Complimentary eBook: Healthcare Forecasting 2.0

About This Blog

In this blog, our experts share regular insights on the global healthcare and pharma industry. Join us as we look at issues in Healthcare Policy, Market Access, Pricing and Reimbursement and R&D. Comments are welcome!
Download an extract — The New REAlity of Relative Effectiveness Assessment: International Comparison of Evolving Requirements

Enter your email address to follow this blog and receive notifications of new posts by email.

Download an Extract of Payer-Industry Partnerships in the Emerging Markets: Best Practices for Successful Market Access of New Pharmaceuticals
Read the complimentary special report on UK Drug Reimbursement: What would change with Value-Based Pricing?

IHS Healthcare Twitter feed

Follow

Get every new post delivered to your Inbox.

Join 155 other followers